103 results
Page 4 of 6
6-K
EX-99.1
b3a1sxk08nx8
3 Jun 22
Sanofi will evaluate KIMMTRAK in combination with SAR444245 as part of its ongoing Phase 1 study in advanced unresectable or metastatic skin cancers
4:05pm
6-K
EX-99.3
mlswbcfun8dj 2eyp9
11 May 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:08am
6-K
td5nfp6ck0hyz3hg6
11 May 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:08am
424B7
ml7lw9w
5 May 22
Prospectus with selling stockholder info
12:00am
6-K
EX-99.1
vos6i jkolkfw
14 Apr 22
Current report (foreign)
4:11pm
F-3ASR
dnqqhyz9kiut6f6
4 Apr 22
Automatic shelf registration (foreign)
4:08pm
F-3ASR
EX-4.4
fcv9soybd0zuus cr
4 Apr 22
Automatic shelf registration (foreign)
4:08pm
6-K
EX-99.1
ltsg6d1g8jzfrc4
4 Apr 22
European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
4:06pm
6-K
EX-99.1
uut2iftf
3 Mar 22
Immunocore Reports Full Year 2021 Financial Results
7:01am
6-K
EX-99.1
vmzzub6h2cd pu0axof6
26 Jan 22
Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma
4:29pm
6-K
EX-99.1
r0ewevcb0 78d
7 Dec 21
Immunocore announces initial Phase 1 data of ImmTAC® candidate IMC-C103C targeting MAGE-A4
4:10pm
6-K
zs4tqklb72c8sn
10 Nov 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:01am
6-K
EX-99.3
suojk3vjw5zkb
10 Nov 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:01am
6-K
EX-99.1
mhqzkqjq ni80
24 Aug 21
Current report (foreign)
4:33pm
6-K
EX-99.3
cds3eg 2933j3yqwgbw
11 Aug 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:00am
6-K
bgh0dilc
11 Aug 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:00am
6-K
9u2p3
12 May 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:00am
6-K
EX-99.3
hc0v4tk
12 May 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:00am